author-photo

Gia Nemsadze

23

Papers

394

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD1-11: Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Differential Assessments of Blood Lipids, Lipid Peroxidation, Antioxidant Status, and Fatty Acids in Women with Uterine Tumors during Menopausal Period

2019 The FASEB Journal
Show All
- Source
- Cite
- Save
Citations (0)
Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Abstract P1-14-01: Final analysis of overall survival (OS) for the epoetin alfa (EPO) phase 3 study, EPO-ANE-3010, of EPO plus standard supportive care (SOC) versus SOC in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-Neulasta ® in the prophylactic treatment of chemotherapy-induced neutropenia

2017 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (16)
Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-neulasta® in the prophylaxis of chemotherapy-induced neutropenia

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (33)
Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)